

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* Announcement on the Result of the Reduction in Shareholding of the Shareholder” published by Shanghai Junshi Biosciences Co., Ltd.* on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 19 August 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as a non-executive Director; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.

** For identification purposes only*

Shanghai Junshi Biosciences Co., Ltd.*

Announcement on the Result of the Reduction in Shareholding of the Shareholder

The Board of Directors of the Company, all Directors and relevant shareholders guarantee that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal responsibility for the truthfulness, accuracy and completeness of the contents herein.

Important notice:

- Basic shareholding information of the substantial shareholder

Before the plan for the reduction in shareholding, Shanghai Tanying Investment Partnership (LP) (“Shanghai Tanying”) held 59,459,326 shares of Shanghai Junshi Biosciences Co., Ltd. (the “Company”), all of which were A shares, accounting for 5.7914% of total share capital of the Company. The aforesaid shares are shares acquired before the initial public offering and listing on the Science and Technology Innovation Board of Shanghai Stock Exchange (the “IPO”) of the Company, and the restrictions on sale have been lifted and the shares have been listed for trading since 15 July 2021.

- Result of the plan for the reduction in shareholding

On 24 April 2026, the Company disclosed the “Announcement on the Plan for the Reduction in the Shareholding of the Shareholders” (Announcement No.: Lin 2026-025) on the website of Shanghai Stock Exchange (www.sse.com.cn). Due to the maturity of the fund and liquidity arrangements, Shanghai Tanying planned to reduce the shareholding in the Company by no more than 20,533,797 shares in total through block trading, and the total reduction ratio did not exceed 2% of the total share capital of the Company. The duration of reduction in shareholding was from 20 May 2026 to 19 August 2026.

The Company received the “Notice on the Result of the Reduction in Shareholding

of Junshi Biosciences” (《關於君實生物減持股份結果的告知函》) issued by Shanghai Tanying recently. As of the date of this announcement, the time period of the plan for the reduction in shareholding has expired. During the duration of the plan for the reduction in shareholding, Shanghai Tanying reduced 20,533,700 A shares of the Company in total through block trading, and the total reduction ratio accounted for 2% of the total share capital of the Company.

I. Basic Information on the Subject of the Reduction in Shareholding Before the Reduction in Shareholding

Name of shareholder	Shanghai Tanying
Capacity of shareholder	Controlling shareholder, actual controller and party acting in concert ☐ Yes ☒ No Shareholder directly holding more than 5% of shares ☒ Yes ☐ No Director, supervisor and senior management ☐ Yes ☒ No Others: Not applicable
Number of shares held	59,459,326 shares
Shareholding percentage	5.7914%
Source of shares currently held	Acquired prior to the IPO: 59,459,326 shares

The aforesaid subject entity of the reduction in shareholding has parties acting in concert:

	Name of shareholder	Number of shares held (shares)	Shareholding percentage	Reasons for acting in concert
Group 1	Shanghai Tanying	59,459,326	5.7914%	The executive partner of Shanghai Tanying is

	Loyal Valley Capital Advantage Fund II LP	7,842,673	0.7639%	Shanghai Loyal Valley Investment Management Co., Ltd., and the actual controller is Mr. Lin Lijun. Shares of the Company held by Shanghai Tanying are A shares. Loyal Valley Capital Advantage Fund II LP and LVC Renaissance Fund LP are partnerships beneficially controlled by Mr. Lin Lijun, and the nature of the shares held by them is H shares.
	LVC Renaissance Fund LP	7,916,000	0.7710%	
	Total	75,217,999	7.3263%	

II. Result of the Plan for the Reduction in Shareholding

(i) Major shareholders disclose the result of the plan for the reduction due to the following matter:

Disclosed share reduction period has expired

Name of shareholder	Shanghai Tanying
First disclosure date of the plan for the reduction in shareholding	24 April 2026
Number of shares reduced	20,533,700 share
Duration of reduction in shareholding	8 June 2026~19 August 2026

Methods for reduction in shareholding and corresponding number of shares reduced	For reduction in shareholding through block trades: 20,533,700 share
Price range of reduction in shareholding	RMB28.73~39.87 per share
Total amount of reduction in shareholding	RMB706,846,562.00
Completion of reduction in shareholding	Not yet completed: 97 shares
Percentage of reduction in shareholding	2%
Percentage of proposed reduction in shareholding	Not more than: 2%
Current shareholding	38,925,626 shares
Current shareholding percentage	3.7914%

- (ii) Whether the reduction in shareholding is in compliance with the relevant laws and regulations and the business rules of the stock exchange ☒Yes ☐No
- (iii) Whether the actual reduction in shareholding is consistent with the plan and undertakings previously disclosed ☒Yes ☐No
- (iv) Whether the reduction was not implemented after the expiration of the reduction period ☐Not implemented ☒Implemented
- (v) Whether the actual reduction failed to achieve the minimum reduction quantity (ratio) specified in the reduction plan ☐Not achieved ☒Achieved
- (vi) Whether to terminate the share reduction plan in advance ☐Yes ☒No
- (vii) Whether there is any violation of the plan or other undertakings ☐Yes ☒No

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*

Board of Directors

20 August 2026